Child Health Evaluative Sciences, The Research Institute Hospital for Sick Children, Toronto, ON, Canada.
Department of Critical Care Medicine, The Hospital for Sick Children, Toronto, ON, Canada.
Pediatr Crit Care Med. 2020 Apr;21(4):e170-e176. doi: 10.1097/PCC.0000000000002236.
Despite the ubiquitous role of pharmacotherapy in the care of critically ill children, descriptions of the extent of pharmacotherapy in critical illness are limited. Greater understanding of drug therapy can help identify clinically important associations and assist in the prioritization of efforts to address knowledge gaps. The objectives of this study were to describe the diversity, volume, and patterns of pharmacotherapy in critically ill children.
A retrospective cohort study was performed with patient admissions to the ICU between July 31, 2006, and July 31, 2015.
The study took place at a single, free-standing, pediatric, quaternary center.
Eligible patient admissions were admitted to the ICU for more than 6 hours and received one or more drug administration. There were a total 17,482 patient-admissions and after exclusion of 283 admissions (2%) with no documented enteral or parenteral drug administration, 17,199 eligible admissions were studied.
None.
The 17,199 eligible admissions were admitted to the ICU for 2,208,475 hours and received 515 different drugs. The 1,954,171 administrations were 894,709 (45%) enteral administrations, 998,490 (51%) IV injections and 60,972 (3%) infusions. Infusions were administered for 4,476,538 hours. Twelve-thousand two-hundred seventy-three patients (71%) were administered five or more different drugs on 80,943 of patient days (75%). The 10 most commonly administered drugs comprised of 834,441 administrations (43%).
Drug administration in the ICU is complex, involves many medications, and the potential for drug interaction and reaction is compounded by the volume and diversity of therapies routinely provided in ICU. Further evaluation of polytherapy could be used to improve outcomes and enhance the safety of pharmacotherapy in critically ill children.
尽管药物治疗在危重症儿童的治疗中无处不在,但对危重症中药物治疗的范围的描述有限。更多地了解药物治疗可以帮助识别临床相关的关联,并有助于确定优先事项,以解决知识空白。本研究的目的是描述危重症儿童药物治疗的多样性、用量和模式。
这是一项回顾性队列研究,研究对象为 2006 年 7 月 31 日至 2015 年 7 月 31 日期间入住 ICU 的患者。
该研究在一家独立的、专门的儿科四级中心进行。
符合条件的患者入住 ICU 超过 6 小时,并接受了一种或多种药物治疗。共有 17482 例患者入院,排除了 283 例(2%)无记录的肠内或胃肠外药物治疗的入院病例后,共研究了 17199 例符合条件的入院病例。
无。
这 17199 例符合条件的患者入住 ICU 时间为 2208475 小时,接受了 515 种不同的药物治疗。1954171 次给药中,894709 次(45%)为肠内给药,998490 次(51%)为 IV 注射,60972 次(3%)为输液。输液给药时间为 4476538 小时。1273 名患者(71%)在 80943 个患者日(75%)中接受了 5 种或 5 种以上不同的药物治疗。10 种最常用的药物给药 834441 次(43%)。
在 ICU 中,药物给药复杂,涉及多种药物,而 ICU 中常规提供的治疗方法的数量和多样性使药物相互作用和反应的可能性更加复杂。进一步评估多疗法可以提高治疗效果,提高危重症儿童药物治疗的安全性。